SEC Form 4 · accession 0001144204-18-050799
Y-mAbs Therapeutics, Inc. · YMAB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James Healy
Director
Period of report
Sep 21, 2018
Accepted (ET)
Sep 25, 2018 · 8:41 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001722964
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 21, 2018 | P | 500,000 | $16.00 | A | 2,104,278 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Such shares of the Company's Common Stock are owned by Sofinnova Venture Partners X, L.P. ("Sofinnova X"). The Reporting Person is a managing member of Sofinnova Management X, L.L.C., the General Partner of Sofinnova X, and as such has shared voting and dispositive power over such shares with Dr. Anand Mehra and Michael F. Powell, Ph.D., the other managing members of Sofinnova Management X, L.L.C. The Reporting Person disclaims beneficial ownership of the reported securities, except to the extent of any pecuniary interest therein.